Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.
Public ClinicalTrials.gov record NCT00328627. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.
Study identification
- NCT ID
- NCT00328627
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,554 participants
Conditions and interventions
Conditions
Interventions
- Alogliptin Drug
- Alogliptin placebo Drug
- Pioglitazone Drug
- Pioglitazone placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Feb 29, 2008
- Completion
- Feb 29, 2008
- Last update posted
- Apr 3, 2013
2006 – 2008
United States locations
- U.S. sites
- 72
- U.S. states
- 28
- U.S. cities
- 72
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Columbiana | Alabama | — | — |
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Searcy | Arkansas | — | — |
| Not listed | Sherwood | Arkansas | — | — |
| Not listed | Burbank | California | — | — |
| Not listed | Foothill Ranch | California | — | — |
| Not listed | Irvine | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Temecula | California | — | — |
| Not listed | Tustin | California | — | — |
| Not listed | Colorado Springs | Colorado | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Hollywood | Florida | — | — |
| Not listed | Kissimmee | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | New Port Richey | Florida | — | — |
| Not listed | Pembroke Pines | Florida | — | — |
| Not listed | Pinellas Park | Florida | — | — |
| Not listed | Sarasota | Florida | — | — |
| Not listed | Vero Beach | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Roswell | Georgia | — | — |
| Not listed | Savannah | Georgia | — | — |
| Not listed | Warner Robins | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Peoria | Illinois | — | — |
| Not listed | Lafayette | Indiana | — | — |
| Not listed | South Bend | Indiana | — | — |
| Not listed | Waterloo | Iowa | — | — |
| Not listed | Munfordville | Kentucky | — | — |
| Not listed | Baton Rouge | Louisiana | — | — |
| Not listed | Marrero | Louisiana | — | — |
| Not listed | Elkridge | Maryland | — | — |
| Not listed | Prince Frederick | Maryland | — | — |
| Not listed | Towson | Maryland | — | — |
| Not listed | Marlborough | Massachusetts | — | — |
| Not listed | Ann Arbor | Michigan | — | — |
| Not listed | Cadillac | Michigan | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Livonia | Michigan | — | — |
| Not listed | Kansas City | Missouri | — | — |
| Not listed | North Las Vegas | Nevada | — | — |
| Not listed | Blackwood | New Jersey | — | — |
| Not listed | Trenton | New Jersey | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Statesville | North Carolina | — | — |
| Not listed | Gallipolis | Ohio | — | — |
| Not listed | Marion | Ohio | — | — |
| Not listed | Clinton | Oklahoma | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Allentown | Pennsylvania | — | — |
| Not listed | Altoona | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Alcoa | Tennessee | — | — |
| Not listed | Milan | Tennessee | — | — |
| Not listed | Morristown | Tennessee | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Carrollton | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Temple | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Burlington | Vermont | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00328627, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2013 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00328627 live on ClinicalTrials.gov.